On Monday and Tuesday Australia’s medicinal cannabis industry was absolutely smoked by the market, making it the worst performing area of the market by some distance.
But thankfully for its investors, today it is the turn of medicinal cannabis shares to do the smoking.
Here are the highlights from the industry after lunch:
- The Auscann Group Holdings Ltd (ASX: AC8) share price has surged 28% higher to $1.60.
- The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is up 8% to 13 cents.
- The Cann Group Ltd (ASX: CAN) share price has jumped 14% to $2.84.
- The Cannpal Animal Therapeutics Ltd (ASX: CP1) share price is 7% higher at 23 cents.
- The Creso Pharma Ltd (ASX: CPH) share price is up 12% to 90.5 cents.
- The MMJ Phytotech Ltd (ASX: MMJ) share price is 13.5% higher at 46.5 cents.
- The Hydroponics Company Ltd (ASX: THC) share price has climbed 8% to 77 cents.
- The Zelda Therapeutics Ltd (ASX: ZLD) share price is 14% higher at 12.5 cents.
Why are cannabis shares climbing higher?
As well as investors flicking the risk-on switch again today, these gains can be attributed to the moves higher that were made by their international peers overnight. Canadian cannabis giants Canopy Growth Corp and Aurora Cannabis both surged higher on the Toronto stock exchange on Tuesday.
Canopy Growth Corp’s shares rose 19% during trade on Tuesday, adding approximately C$850 million to its market capitalisation.
Aurora Cannabis went one better with a 25% gain, adding over C$1 billion to its market capitalisation.
Should you invest?
As I have said previously, I think one or two of these shares could have bright futures ahead of them if they can dominate the Australian market.
But given how early it is and how competitive the market is, it is reasonably hard to predict which companies will emerge as market leaders.
In light of this, I continue to believe that investors ought to hold out until it becomes clear which companies will rise to the top.
For now, these top growth shares could be better investment options in my opinion.
For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..
But knowing which blue chips to buy, and when, can be fraught with danger.
The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."
Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.
The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.
Click here to claim your free report.
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.